Pregnancy Management in Four Women with Alemtuzumab-Induced Graves' Disease
Four women with alemtuzumab-induced Graves' disease (GD) were observed, with two achieving good thyroid control on anti-thyroid drugs (ATD) during pregnancy. One managed with levothyroxine alone had partial control; another achieved full control using a combination of ATD and levothyroxine. No severe adverse pregnancy outcomes were noted, but six newborns experienced transient thyroid dysfunction requiring treatment.
- Tags
- #MSResearch
- Most relevant to
- —
- Human efficacy
- Not yet assessed
- Mechanism
- Not yet assessed
- Evidence strength
- Not yet assessed
- Outcome
- Not yet assessed
Why it matters
This study provides insights into managing thyroid function in pregnant women with GD related to alemtuzumab, an area lacking extensive research. The findings suggest potential strategies for thyroid management in this population, but the small sample size limits generalizability.
What this does not prove
The study is based on a limited number of cases without formal comparison or control groups, reducing the robustness of the conclusions.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Not reported
- Participants / samples
- Not reported
- Randomised
- No
- Controlled
- No
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- 2026-09-28
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Not classified
Original sources
- Primary evidenceManagement of pregnancy in patients with Graves' disease secondary to alemtuzumab: a case series and literature review. ↗DOI: 10.3389/fendo.2026.1955471
Supporting passages (11)
sample size basisMETHODS: We reviewed the clinical course and therapeutic management of four pregnant women affected with alemtuzumab-induced GD or TRAb-positive hypothyroidism followed at our Institution, and seven additional cases published in literature.
randomizedNo
controlledNo
publication date2026-09-28
interventionTwo women had alemtuzumab-induced TRAb positive hypothyroidism; during pregnancy thyroid function was partially controlled with levothyroxine (LT4) alone in one case, and fully controlled with block and replace (ATD and LT4) in the other case.
primary endpointRESULTS: At our institution two patients with alemtuzumab-induced GD (one diagnosed before pregnancy, the other during the third trimester) showed a good control of thyroid function on anti-thyroid drugs (ATD).
findingsRESULTS: At our institution two patients with alemtuzumab-induced GD (one diagnosed before pregnancy, the other during the third trimester) showed a good control of thyroid function on anti-thyroid drugs (ATD).
findingsTwo women had alemtuzumab-induced TRAb positive hypothyroidism; during pregnancy thyroid function was partially controlled with levothyroxine (LT4) alone in one case, and fully controlled with block and replace (ATD and LT4) in the other case.
findingsNo pregnancy or fetal/neonatal negative outcomes were observed, except for preterm delivery of a healthy baby in Case 3, due to emergency cesarean section for pre-eclampsia progressing to HELLP syndrome.
findingsSix newborns developed transient thyroid dysfunction, often requiring treatment and later resolved.
limitationsTitle: Management of pregnancy in patients with Graves' disease secondary to alemtuzumab: a case series and literature review.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.